Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Arvinas stock

ARVN
US04335A1051
A2N6VP

Price

0
Today +/-
-0
Today %
-0 %
P

Arvinas stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Arvinas stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Arvinas stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Arvinas stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Arvinas's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Arvinas Stock Price History

DateArvinas Price
9/30/20240 undefined
9/27/20240 undefined
9/26/20240 undefined
9/25/20240 undefined
9/24/20240 undefined
9/23/20240 undefined
9/20/20240 undefined
9/19/20240 undefined
9/18/20240 undefined
9/17/20240 undefined
9/16/20240 undefined
9/13/20240 undefined
9/12/20240 undefined
9/11/20240 undefined
9/10/20240 undefined
9/9/20240 undefined
9/6/20240 undefined
9/5/20240 undefined
9/4/20240 undefined
9/3/20240 undefined

Arvinas Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Arvinas, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Arvinas from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Arvinas’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Arvinas. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Arvinas’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Arvinas’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Arvinas’s growth potential.

Arvinas Revenue, EBIT and net profit per share

DateArvinas RevenueArvinas EBITArvinas Net Income
2029e0 undefined0 undefined0 undefined
2028e0 undefined0 undefined0 undefined
2027e0 undefined0 undefined0 undefined
2026e0 undefined0 undefined0 undefined
2025e0 undefined0 undefined0 undefined
2024e0 undefined0 undefined0 undefined
20230 undefined0 undefined0 undefined
20220 undefined0 undefined0 undefined
20210 undefined0 undefined0 undefined
20200 undefined0 undefined0 undefined
20190 undefined0 undefined0 undefined
20180 undefined0 undefined0 undefined
20170 undefined0 undefined0 undefined
20160 undefined0 undefined0 undefined

Arvinas Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
201620172018201920202021202220232024e2025e2026e2027e2028e2029e
0.010.010.010.040.020.050.130.080.220.20.250.470.711
-16.67100.00207.14-51.16119.05184.78-40.46180.77-8.2224.8888.4550.3240.93
--------------
00000000000000
-16-24-43-51-124-195-263-401-338-357-341-204480
-266.67-342.86-307.14-118.60-590.48-423.91-200.76-514.10-154.34-177.61-135.86-43.136.75-
-12-28-239-70-119-191-282-367-245-324-303-12262179
-133.33753.57-70.7170.0060.5047.6430.14-33.2432.24-6.48-59.74-150.82188.71
31.231.231.232.939.55053.255.5000000
--------------
Details

Keystats

ⓘ

Revenue and Growth

The Arvinas Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Arvinas is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (B)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (B)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (M)OTHER EQUITY (k)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (k)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (B)
20162017201820192020202120222023
               
0.040.040.190.280.691.51.211.26
0252.8011510
1.412.26.37.410.777.2
00000000
0.30.32.83.76.124.226.912
0.040.070.20.290.71.551.241.28
0.61.33.610.714.316.617.814
00000000
00000000
00000000
00000000
0000012.510.810.4
0.61.33.610.714.329.128.624.4
0.040.070.20.30.721.581.271.3
               
57.862.700000.10.1
000.440.61.131.471.552
-33.8-62.4-302.3-372.6-491.9-682.9-965.4-1,332.7
00-200100600-4,600-19,200-3,100
00000000
240.3136.6226.6642.2781.7564.9660
1.60.62.84.67.131.35.7110
1.73.548.319.824.260.575.6
6.713.616.12022.2206.2228.9163.7
00000000
10020020000000
10.117.923.132.949.1261.7295.1349.3
0.30.2222110.8
00000000
3.648.637.640.124537.2407.8386.7
3.948.839.642.126538.2408.8387.5
1466.762.77575.1799.9703.9736.8
0.040.070.20.30.721.581.271.4
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Arvinas provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Arvinas's financial health and stability.

Assets

Arvinas's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Arvinas must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Arvinas after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Arvinas's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (k)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20162017201820192020202120222023
-14-24-41-70-119-191-282-367
00013464
00000000
-528127-5678-82-44
00234162124160130
00000000
0000001111
-195-16-40-89559-273-347
0-1-2-6-6-4-6-2
-2020-179-93164-1,313242203
-1921-176-86170-1,308249206
00000000
001,00000000
001661395322834391
001681395042784374
-----27.00-4.00--17.00
00000000
-3925-276579-475-26230
-19.74.1-18.9-46.8-96.2554.7-280.3-350.7
00000000

Arvinas stock margins

The Arvinas margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Arvinas. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Arvinas.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Arvinas's sales revenue. A higher gross margin percentage indicates that the Arvinas retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Arvinas's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Arvinas's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Arvinas's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Arvinas. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Arvinas's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Arvinas Margin History

Arvinas Gross marginArvinas Profit marginArvinas EBIT marginArvinas Profit margin
2029e0 %0 %0 %
2028e0 %0 %0 %
2027e0 %0 %0 %
2026e0 %0 %0 %
2025e0 %0 %0 %
2024e0 %0 %0 %
20230 %0 %0 %
20220 %0 %0 %
20210 %0 %0 %
20200 %0 %0 %
20190 %0 %0 %
20180 %0 %0 %
20170 %0 %0 %
20160 %0 %0 %

Arvinas Stock Sales Revenue, EBIT, Earnings per Share

The Arvinas earnings per share therefore indicates how much revenue Arvinas has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Arvinas earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Arvinas's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Arvinas’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Arvinas's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Arvinas Revenue, EBIT and net profit per share

DateArvinas Sales per ShareArvinas EBIT per shareArvinas Earnings per Share
2029e0 undefined0 undefined0 undefined
2028e0 undefined0 undefined0 undefined
2027e0 undefined0 undefined0 undefined
2026e0 undefined0 undefined0 undefined
2025e0 undefined0 undefined0 undefined
2024e0 undefined0 undefined0 undefined
20230 undefined0 undefined0 undefined
20220 undefined0 undefined0 undefined
20210 undefined0 undefined0 undefined
20200 undefined0 undefined0 undefined
20190 undefined0 undefined0 undefined
20180 undefined0 undefined0 undefined
20170 undefined0 undefined0 undefined
20160 undefined0 undefined0 undefined

Arvinas business model

Arvinas Inc. is a biopharmaceutical company based in New Haven, Connecticut, USA. It was founded in 2013 by Dr. Craig Crews, who also serves as a scientific advisor to the company. The company's mission is to develop innovative therapies based on Proteolysis-Targeting Technology (PROTAC). This technology uses artificially engineered molecules to identify and mark specific proteins in the body, which are then degraded by the body's own enzymes. This approach can treat diseases caused by misfolded or overexpressed proteins. Arvinas' business model is to develop multiple drug candidates based on this platform. The company collaborates with leading academic institutions and biotechnology companies to identify targets that can be reached using PROTAC technology. Additionally, the company has a proprietary pipeline of drug candidates in various stages of clinical development. Arvinas operates in several therapeutic areas, including cancer, immunology, and metabolic disorders. Their drug candidates include ARV-110, a PROTAC targeting the androgen receptor protein (AR), which is a potential therapy for patients with resistant prostate cancer. Similarly, Arvinas' other drug candidates target specific proteins associated with certain diseases. Another drug from the company is ARV-471, an orally administered degrader targeting the estrogen receptor alpha (ERa), which plays a role in breast cancer. ARV-471 is a potential therapy for patients with rare subtypes of breast cancer. Arvinas also has partnerships in various areas of drug development. For example, in collaboration with Pfizer, they are developing ARV-411, a PROTAC targeting the menin-1 protein, which is involved in acute myeloid leukemia. Arvinas also has a partnership with Genentech, a subsidiary of Roche, for the use of PROTAC in the treatment of cancer. Overall, Arvinas is an innovative biopharmaceutical company based on Proteolysis-Targeting Technology, focusing on the development of comprehensive therapeutic approaches. With numerous partnerships and a diverse pipeline, the company is well-positioned to play a significant role in drug development. Arvinas is one of the most popular companies on Eulerpool.com.

Arvinas SWOT Analysis

Strengths

Arvinas Inc has numerous strengths that contribute to its position as a leading company in the biotechnology industry. One of its key strengths is its innovative approach to targeting and degrading disease-causing proteins, which sets it apart from traditional therapies that merely inhibit protein function. This unique and groundbreaking technology gives Arvinas a competitive edge over its peers.

The company has an impressive portfolio of drug candidates targeting various diseases, including some with high unmet medical needs. This diversified pipeline reduces the risk associated with a single product focus and provides potential for revenue growth across multiple therapeutic areas.

Arvinas Inc also benefits from its strategic collaborations with major pharmaceutical companies, which provide access to additional resources, expertise, and potential partnership opportunities. These collaborations validate Arvinas' technology platform and enhance its overall credibility in the industry.

Weaknesses

Despite its strengths, Arvinas Inc faces certain weaknesses that could hinder its growth and success. One of the main challenges is that the company's protein degradation technology is still in early stages of development. This means there are uncertainties and risks associated with clinical development, regulatory approvals, and commercialization, which could impact the company's ability to deliver on its promises.

Additionally, as a relatively small biotech company, Arvinas Inc may face resource constraints compared to larger industry players. Limited financial capabilities and resources could limit the speed at which the company can advance its pipeline, execute on its business strategy, and compete effectively in the market.

Opportunities

Arvinas Inc operates in an industry with significant growth prospects. The increasing prevalence of complex diseases and the need for more effective therapies present ample opportunities for the company to address unmet medical needs and capture a larger market share.

Moreover, the expansion of strategic collaborations and partnerships can bring additional resources, funding, and expertise to Arvinas, which can help accelerate the development and commercialization of its drug candidates. The company can leverage these opportunities to further establish itself as a dominant player in the biotechnology space.

Threats

Arvinas Inc faces several threats that could impede its growth and success. One major threat is the intense competition within the biotechnology industry. The presence of numerous established biotech companies, as well as new entrants, increases competitive pressures and the risk of market saturation. Arvinas must continuously innovate, differentiate its products, and demonstrate superior clinical efficacy to stay ahead of the competition.

Additionally, regulatory and reimbursement challenges pose a threat to Arvinas' ability to bring its products to market and realize significant revenue. Stringent regulations, pricing pressures, and changes in healthcare policies can impact the company's ability to secure favorable market access and generate substantial sales.

Arvinas Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Arvinas historical P/E ratio, EBIT multiple, and P/S ratio

Arvinas shares outstanding

The number of shares was Arvinas in 2023 — This indicates how many shares 55.5 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Arvinas earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Arvinas's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Arvinas’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Arvinas's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for Arvinas.

Arvinas latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/20240 0  (44.34 %)2024 Q2
3/31/20240 0  (32.91 %)2024 Q1
12/31/20230 0  (-95.64 %)2023 Q4
9/30/20230 0  (26.59 %)2023 Q3
6/30/20230 0  (25.67 %)2023 Q2
3/31/20230 0  (-0.08 %)2023 Q1
12/31/20220 0  (-31.81 %)2022 Q4
9/30/20220 0  (-7.62 %)2022 Q3
6/30/20220 0  (-24.95 %)2022 Q2
3/31/20220 0  (-32.29 %)2022 Q1
1
2
3

Eulerpool ESG Scorecard© for the Arvinas stock

Eulerpool World ESG Rating (EESG©)

55/ 100

🌱 Environment

56

👫 Social

84

🏛️ Governance

26

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept❌
Privacy concept—
Occupational health and safety❌
Catholic✅

Governance (Corporate Governance)

Environmental reporting❌
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Arvinas shareholders

%
Name
Stocks
Change
Date
9.79824 % EcoR1 Capital, LLC6,726,4911,259,42812/31/2023
7.05342 % The Vanguard Group, Inc.4,842,174243,16712/31/2023
6.13763 % RTW Investments L.P.4,213,4834,213,48312/31/2023
6.07150 % BlackRock Institutional Trust Company, N.A.4,168,085357,24412/31/2023
5.43172 % T. Rowe Price Associates, Inc.3,728,8731,132,89812/31/2023
4.34831 % Avidity Partners Management LP2,985,117370,15712/31/2023
3.65292 % Bellevue Asset Management AG2,507,731382,53112/31/2023
3.55423 % Citadel Advisors LLC2,439,9811,815,40312/31/2023
2.46999 % Nextech Invest, Ltd.1,695,6451,408,39412/31/2023
2.28681 % ArrowMark Colorado Holdings, LLC1,569,895-517,39712/31/2023
1
2
3
4
5
...
10

Arvinas Executives and Management Board

Dr. John Houston63
Arvinas Chairman of the Board, President, Chief Executive Officer (since 2017)
Compensation 9.55 M
Dr. Ronald Peck57
Arvinas Chief Medical Officer
Compensation 3.53 M
Dr. Ian Taylor60
Arvinas Chief Scientific Officer
Compensation 3.52 M
Mr. Sean Cassidy
Arvinas Chief Financial Officer
Compensation 3.51 M
Mr. John Young58
Arvinas Independent Director
Compensation 761,797
1
2
3

Arvinas Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Bayer Stock
Bayer
SupplierCustomer0,830,87-0,21-0,58-0,61-0,22
Roche Holding Stock
Roche Holding
SupplierCustomer0,480,830,080,24-0,070,45
Pfizer Stock
Pfizer
SupplierCustomer-0,450,690,180,36-0,390,47
1

Most common questions regarding Arvinas

What values and corporate philosophy does Arvinas represent?

Arvinas Inc represents values of innovation, integrity, and commitment to advancing healthcare through targeted protein degradation. The company's corporate philosophy focuses on developing novel therapeutics using their proprietary PROTAC® platform. Arvinas Inc strives to discover and deliver transformative medicines that address significant unmet medical needs. By harnessing the power of protein degradation, Arvinas Inc aims to revolutionize the treatment of diseases such as cancer and other serious conditions. Through their cutting-edge research and dedication to improving patients' lives, Arvinas Inc continues to be a leader in the field of targeted protein degradation.

In which countries and regions is Arvinas primarily present?

Arvinas Inc is primarily present in the United States.

What significant milestones has the company Arvinas achieved?

Arvinas Inc, a leading biotechnology company, has achieved several significant milestones. The company successfully developed and secured approval for its lead product candidate, ARV-110, which targets the androgen receptor protein for the treatment of metastatic castration-resistant prostate cancer. Arvinas has also advanced its second program, ARV-471, for the treatment of breast cancer, into clinical trials. Furthermore, the company has entered into strategic collaborations with leading pharmaceutical companies to expand the application of its PROTAC® technology platform. Arvinas' dedication to innovative drug development and strategic partnerships showcases its commitment to revolutionizing the field of targeted protein degradation.

What is the history and background of the company Arvinas?

Arvinas Inc, founded in 2013, is a biopharmaceutical company based in New Haven, Connecticut. The company focuses on developing targeted protein degradation therapies to treat various diseases such as cancer and genetically driven conditions. Arvinas utilizes its proprietary PROTAC® (PROteolysis TArgeting Chimeras) platform, allowing selective protein degradation and removal from cells. This innovative approach offers the potential for more effective and precise treatments. Arvinas has partnered with pharmaceutical companies and has a diverse pipeline targeting different diseases. With its cutting-edge technology and strategic partnerships, Arvinas aims to revolutionize the field of protein degradation therapy for the benefit of patients worldwide.

Who are the main competitors of Arvinas in the market?

Some of the main competitors of Arvinas Inc. in the market include Bristol-Myers Squibb Company, GlaxoSmithKline plc, and Pfizer Inc.

In which industries is Arvinas primarily active?

Arvinas Inc is primarily active in the biotechnology industry.

What is the business model of Arvinas?

The business model of Arvinas Inc revolves around developing and commercializing protein degradation therapies for various diseases. By leveraging their proprietary PROTAC® (PROteolysis-TArgeting Chimeras) platform, Arvinas aims to address diseases that traditional small molecules and biologics struggle to target effectively. This innovative approach targets disease-causing proteins for degradation, which can potentially lead to more efficient and precise treatments. Arvinas focuses on collaborations with pharmaceutical partners to advance their product pipeline and expand their reach in therapeutic areas such as oncology, neurology, and rare diseases. With their cutting-edge technology and strategic partnerships, Arvinas Inc strives to provide breakthrough therapies for patients in need.

What is the P/E ratio of Arvinas 2024?

The P/E ratio cannot be calculated for Arvinas at the moment.

What is the P/S ratio of Arvinas 2024?

The P/S cannot be calculated for Arvinas currently.

What is the AlleAktien quality score of Arvinas?

The AlleAktien quality score for Arvinas is 4/10.

What is the revenue of Arvinas 2024?

The revenue cannot currently be calculated for Arvinas.

How high is the profit of Arvinas 2024?

The profit cannot currently be calculated for Arvinas.

What is the business model of Arvinas

Arvinas Inc is a biotechnology company based in New Haven, Connecticut, USA. They specialize in the development of therapeutics based on protein degradation. Their goal is to treat diseases that traditional approaches, such as enzyme inhibition or receptor blockade, are not sufficient for. The basic principle of protein degradation is to specifically break down faulty or diseased proteins by targeting them. Arvinas focuses on the development of PROTACs (Proteolysis-Targeting Chimeras), which consist of two binding molecules. One molecule binds to the faulty protein, while the other molecule marks it for degradation by the body's own proteasome. Arvinas' core areas include oncology, neurodegeneration, inflammatory diseases, and rare genetic disorders. By manipulating proteins, they potentially can develop individualized treatment approaches for each disease. In oncology, Arvinas is focused on developing therapeutics for breast cancer, prostate cancer, and lung cancer. In neurodegeneration, their aim is to effectively combat Alzheimer's, Parkinson's, or ALS. In inflammation research, their focus is on rheumatoid arthritis and fibrosis. Arvinas has recently entered into partnerships with leading pharmaceutical companies. They are working with Pfizer on the development of immuno-oncology therapeutics. Another partnership exists with Genentech, a sister company of Roche, for the discovery and development of therapeutics in the field of neurodegeneration. However, Arvinas is not only involved in drug development but also offers research services for PROTAC development. They explore new target molecules and develop specific PROTACs for pharmaceutical industry clients. This is an important growth market for the company as more companies recognize the advantages of protein degradation as a therapeutic approach. Another significant growth field for Arvinas is the use of "traps." These are synthetic molecules that mark and intercept faulty proteins before they reach their target location. Arvinas has developed their own technologies for this and has already achieved initial successes, particularly in cancer treatment. Overall, Arvinas Inc is a promising biotechnology company with a broad pipeline of therapeutics based on protein degradation. With strong partnerships with various companies and an open research infrastructure, they will be able to continue their research and development of therapeutics for a variety of diseases.

What is the Arvinas dividend?

Arvinas pays a dividend of 0 USD distributed over payouts per year.

How often does Arvinas pay dividends?

The dividend cannot currently be calculated for Arvinas or the company does not pay out a dividend.

What is the Arvinas ISIN?

The ISIN of Arvinas is US04335A1051.

What is the Arvinas WKN?

The WKN of Arvinas is A2N6VP.

What is the Arvinas ticker?

The ticker of Arvinas is ARVN.

How much dividend does Arvinas pay?

Over the past 12 months, Arvinas paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Arvinas is expected to pay a dividend of 0 USD.

What is the dividend yield of Arvinas?

The current dividend yield of Arvinas is .

When does Arvinas pay dividends?

Arvinas pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Arvinas?

Arvinas paid dividends every year for the past 0 years.

What is the dividend of Arvinas?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Arvinas located?

Arvinas is assigned to the 'Health' sector.

Wann musste ich die Aktien von Arvinas kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Arvinas from 10/1/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/1/2024.

When did Arvinas pay the last dividend?

The last dividend was paid out on 10/1/2024.

What was the dividend of Arvinas in the year 2023?

In the year 2023, Arvinas distributed 0 USD as dividends.

In which currency does Arvinas pay out the dividend?

The dividends of Arvinas are distributed in USD.

All fundamentals about Arvinas

Our stock analysis for Arvinas Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Arvinas Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.